Back to News
Market Impact: 0.35
Nuvation Bio Wins FDA Nod For Updated IBTROZI Label Showing 50-Month DOR In ROS1+ Lung Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
The FDA approved Nuvation Bio's supplemental New Drug Application for IBTROZI, updating its label with new long-term efficacy data for treatment-naïve patients with advanced ROS1-positive non-small cell lung cancer. The approval strengthens the drug's clinical positioning in its targeted NSCLC indication and is a positive regulatory milestone for Nuvation Bio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
NUVB0.82
More News
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Boris Vujčić: Integrated, open and resilient: Europe’s strengths in a fragmenting world
- Citizens reiterates Ondas Holdings stock rating on IonStrike updates
- Wells Fargo raises Regeneron stock price target to $925 on execution